NewAmsterdam Pharma Company NV Receivables

NewAmsterdam Pharma Company NV's receivables stands at $18M as of September 2026. That compares with $20M in the prior-year period — down 8.8% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

NewAmsterdam Pharma Company NV reported $18M in receivables versus $20M a year earlier — a 8.8% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $20M in the prior-year period — down 8.8% year over year. Sustained growth in receivables can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how NewAmsterdam Pharma Company NV's receivables evolved across reporting periods, while the comparison chart places NAMS next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.